Uptake of WHO recommendations for first-line antiretroviral therapy in Kenya, Uganda, and Zambia. by Duber, Herbert C et al.
Duber, Herbert C; Dansereau, Emily; Masters, Samuel H; Achan,
Jane; Burstein, Roy; DeCenso, Brendan; Gasasira, Anne; Ikilezi, Glo-
ria; Kisia, Caroline; Masiye, Felix; Njuguna, Pamela; Odeny, Thomas;
Okiro, Emelda; Roberts, D Allen; Gakidou, Emmanuela (2015) Up-
take of WHO recommendations for first-line antiretroviral therapy
in Kenya, Uganda, and Zambia. PloS one, 10 (3). e0120350-. ISSN
1932-6203 DOI: https://doi.org/10.1371/journal.pone.0120350
Downloaded from: http://researchonline.lshtm.ac.uk/4651984/
DOI: 10.1371/journal.pone.0120350
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Uptake of WHO Recommendations for First-
Line Antiretroviral Therapy in Kenya, Uganda,
and Zambia
Herbert C. Duber1*, Emily Dansereau1, Samuel H. Masters1, Jane Achan2, Roy Burstein1,
Brendan DeCenso1, Anne Gasasira1, Gloria Ikilezi2, Caroline Kisia3, Felix Masiye4,
Pamela Njuguna3, Thomas Odeny1, Emelda Okiro1, D. Allen Roberts1,
Emmanuela Gakidou1
1 Institute for Health Metrics and Evaluation, University of Washington, Seattle, WA, United States of
America, 2 Infectious Disease Research Collaboration, Makerere University, Kampala, Uganda, 3 Action
Africa Help-International, Nairobi, Kenya, 4 Department of Economics, University of Zambia, Lusaka,
Zambia
* hduber@uw.edu
Abstract
Introduction
Antiretroviral therapy (ART) guidelines were significantly changed by the World Health Or-
ganization in 2010. It is largely unknown to what extent these guidelines were adopted into
clinical practice.
Methods
This was a retrospective observational analysis of first-line ART regimens in a sample of
health facilities providing ART in Kenya, Uganda, and Zambia between 2007-2008 and
2011-2012. Data were analyzed for changes in regimen over time and assessed for key
patient- and facility-level determinants of tenofovir (TDF) utilization in Kenya and Uganda
using a mixed effects model.
Results
Data were obtained from 29,507 patients from 146 facilities. The overall percentage of pa-
tients initiated on TDF-based therapy increased between 2007-2008 and 2011-2012 from
3% to 37% in Kenya, 2% to 34% in Uganda, and 64% to 87% in Zambia. A simultaneous de-
crease in stavudine (d4T) utilization was also noted, but its use was not eliminated, and
there remained significant variation in facility prescribing patterns. For patients initiating
ART in 2011-2012, we found increased odds of TDF use with more advanced disease at ini-
tiation in both Kenya (odds ratio [OR]: 2.78; 95% confidence interval [CI]: 1.73-4.48) and
Uganda (OR: 2.15; 95% CI: 1.46-3.17). Having a CD4 test performed at initiation was also a
significant predictor in Uganda (OR: 1.43; 95% CI: 1.16-1.76). No facility-level determinants
of TDF utilization were seen in Kenya, but private facilities (OR: 2.86; 95% CI: 1.45-5.66)
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and those employing a doctor (OR: 2.86; 95% CI: 1.48-5.51) were more likely to initiate pa-
tients on TDF in Uganda.
Discussion
d4T-based ART has largely been phased out over the study period. However, significant in-
country and cross-country variation exists. Among the most recently initiated patients,
those with more advanced disease at initiation were most likely to start TDF-based treat-
ment. No facility-level determinants were consistent across countries to explain the ob-
served facility-level variation.
Introduction
Since 2006, the World Health Organization (WHO) has encouraged countries to transition
away from first-line antiretroviral therapies (ART) containing stavudine (d4T), due to well-
recognized toxicities including lactic acidosis, lipodystrophy, and peripheral neuropathy.[1–4]
The 2010 WHO guidelines solidified this recommendation, stating that “countries should take
steps to progressively reduce the use of d4T in first-line regimens.”[5–7] In lieu of d4T, the
WHO and other expert bodies recommended first-line adult ART that utilized a nucleoside re-
verse transcriptase inhibitor (NRTI) backbone of either zidovudine (AZT) or tenofovir (TDF).
[5][8]
While numerous studies comparing d4T-, TDF- and AZT-based regimens have found no
significant differences in efficacy and viral load suppression, patients initiated on d4T-based
treatment are more likely to require ART substitution due to drug toxicity. [9–13] In turn, regi-
men switching may increase the likelihood of drug resistance.[14] TDF combined therapy of-
fers an additional benefit beyond both d4T and AZT, as it can be taken as a single daily dose,
which may portend improved treatment adherence.[13] Based on this advantage, the 2013
WHO consolidated guidelines on the use of ART named a TDF-based therapy as the preferred
option with AZT-based therapies listed as alternatives.
However, AZT- and TDF-based regimens are more expensive than d4T. For instance,
under prices negotiated by the Clinton Health Access Initiative (CHAI) in 2010, triple combi-
nation therapies containing AZT and TDF were at least 80% and 250% more expensive than
those based on d4T, respectively.[15] Since then, CHAI has successfully negotiated substantial-
ly lower prices for AZT and TDF combination therapy, though in 2013 they were still at least
40% and 66% more expensive than d4T-based therapies, respectively. As a result, there was
and continues to be concern that low-income countries hardest hit by the HIV/AIDS epidemic,
as well as donors who supply much of the ART medication, would be hesitant to follow these
new recommendations due to cost.[9][10] Despite cost concerns, many countries in regions of
high HIV/AIDS burden, including Kenya, Uganda, and Zambia, adopted national guidelines
recommending phasing out d4T in favor of either AZT or the more expensive TDF.[16–18]
In this study we examine if WHO and national guidelines to phase out d4T use were
adopted into practice in Kenya, Uganda, and Zambia and the pace at which they were adopted
at the health facility level. We additionally examine the relative uptake of AZT- and TDF-based
therapies, and examine the patient- and facility-level factors associated with the prescription of
TDF-based ART in 2011–2012 in Kenya and Uganda.
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Methods
Facility selection
This study was performed on a subcomponent of facilities selected for a larger facility-based
costing study in Kenya, Uganda, and Zambia. Data were collected between November 2011
and November 2012. In each country, health districts were first stratified by a variety of indica-
tors including wealth, health, and population characteristics. A matrix of possible combina-
tions was then developed, and at least one district from each populated combination was
chosen for inclusion in our study sample. In all countries there was purposeful inclusion of the
capital cities: Nairobi, Kampala, and Lusaka. The following links provide a detailed description
of the study protocol (http://www.healthdata.org/sites/default/files/files/Projects/DCPN/ABCE
%20Project%20Cross-Country%20Protocol.pdf), as well as country-specific policy reports for
the broader facility-based costing study (http://ghdx.healthdata.org/series/access-bottlenecks-
costs-and-equity-abce-project).
The selection of facilities within each district varied by country, but in all cases we sampled
a range of hospitals and health centers, both rural and urban. Health facilities that declined
study participation or where access to the facility was limited due to safety, travel distance, or
time constraints were replaced with other similar facilities within the same district by the coun-
try team when a suitable replacement facility was identified. A subset of facilities that provided
ART services were then selected for inclusion in the ART component of the study described
below.
Facility survey
Six individual survey modules were implemented, collecting information on each facility’s fi-
nances, management, medical consumables, equipment, capacity, services, drugs, and outputs.
This information was supplemented by information obtained from the District Health Man-
agement Team where applicable.
Patient chart selection and record extraction
At each of the designated ART facilities that agreed to patient chart extraction, research assis-
tants asked to see all patient records, specifically requesting charts of deceased patients and
those lost to follow-up, in addition to patients currently enrolled in treatment. Patient charts
were eligible for record extraction if the patient was (or would have been) an adult (age 18 and
older) at the time of extraction, and he/she initiated ART between six and 60 months prior to
the date of chart extraction. Once all available and eligible outpatient records were identified,
the research assistant either estimated the total number of charts with the help of the facility
administrator, or the number of charts, if known, was recorded. In facilities in which there
were fewer than 250 charts, all charts were extracted. If a facility had more than 250 charts, the
total number of charts was divided by 250 and then using the closest integer (x) to that result,
every x chart was selected for record extraction until 250 charts were reviewed.
Data extracted from the patient record included dates related to pre-ART enrollment, ART
initiation, and clinic visits. Demographic characteristics, clinical information (including labo-
ratory testing, WHO staging, and weight), and ART regimen were also recorded.
Data management and analysis
Data were collected electronically using Datstat Illume Survey Manager 5.1 (DatStat Inc., Seat-
tle, WA). All information was then uploaded and analyzed using STATA version 13.0 (Stata-
Corp, College Station, Texas).
Uptake of WHO ART Recommendations
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We excluded charts from facilities that failed to meet a quota of 50 total charts. In addition,
individual facility-years with fewer than 10 patient charts were excluded from descriptive anal-
yses to prevent a small number of charts from exerting excessive influence in a given facility-
year. In addition, patients lacking information about initial regimen, who initiated before turn-
ing 18 years of age, or initiated outside our study period (2008–2012 for Uganda and Kenya
and 2007–2011 for Zambia, based on the timing of data collection) were also excluded. In cases
where WHO stage at initiation was missing, “missing stage at initiation” was included as a cate-
gory in the regression rather than excluding the patient from the analysis.
Antiretroviral treatment regimen at the time of initiation is presented by NRTI backbone
(d4T, AZT, TDF, or other). Patient charts within a facility are classified by the year of ART ini-
tiation. Charts are weighted based on the size of the ART program in the year of ART initiation
as obtained from the facility survey. The total number of adult initiates at a facility was missing
for approximately 5% of facility-years and was linearly interpolated based on existing data
points for that facility. Additionally, values were linearly extrapolated for the most recent year
for all facilities because facility data was only collected through 2010 in Zambia and 2011 in
Kenya and Uganda.
A mixed effects logistic regression model was used to evaluate for both patient and facility
predictors of TDF-based treatment for patients initiating ART in 2011–2012. Separate models
were run for Kenya and Uganda, while Zambia was not included in this part of the analysis due
to lack of variation in regimens for the most recent patient cohort. The logistic regressions
were run at the patient level, with a binary outcome equal to 1 if the patient was initiated on a
TDF-based regimen and 0 if they were initiated on any other regimen. Independent patient
variables included sex, initiation year, age at initiation, WHO stage at initiation, and whether
they had a baseline CD4 test. Independent facility variables included ownership, level of com-
plexity (hospital versus clinic), location, program age, presence of a physician, whether nurses
initiated patients at the facility, and whether any HIV training had occurred at the facility in
the year prior to the survey. Random facility intercepts were also included.
Ethical considerations
Ethical approval for this study was obtained from the University of Washington Human Sub-
jects Division as well as local institutional review boards in Kenya (Kenya Medical Research In-
stitute Ethics Review Committee), Uganda (Makerere University School of Medicine Research
Ethics Committee), and Zambia (The University of Zambia Biomedical Research Ethics Com-
mittee). Patient consent for review of medical records was not obtained, as all information ex-
tracted from clinical charts was anonymized and de-identified prior to analysis.
Role of the funding source
The sponsor had no role in the study design, data collection, data analysis, data interpretation,
or writing of the report. The corresponding author had full access to all the data in the study
and had final responsibility for the decision to submit for publication.
Results
We extracted a total of 33,490 charts from 160 health facilities providing ART services in
Kenya, Uganda, and Zambia. After applying the general exclusion criteria, our analytical data-
set contained 29,507 charts from 146 facilities (13,135 from 51 facilities in Kenya, 8,097 from
47 facilities in Uganda, and 8,275 from 48 facilities in Zambia). Less than 5% of eligible charts
were excluded from descriptive analyses because they initiated in facility-years with insufficient
Uptake of WHO ART Recommendations
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observations or transferred from a different facility. 5.7% of charts were excluded from the re-
gression analyses because they were missing information on one or more of the covariates.
Three-quarters of facilities surveyed were managed by the government, 66% were in urban
areas, and 54% were hospitals (Table 1). The median ART program was six years old at the
time of the survey. The resources and practices surrounding ARV acquisition varied by coun-
try. At the time of the facility survey, most facilities in Kenya (98.0%) and Uganda (87.2%) de-
termined the quantity of ARVs ordered internally, compared to 7.1% in Zambia. Nearly all
Kenyan facilities (98.0%) carried a fixed-dose triple combined form of TDF, compared to less
than half of Uganda facilities (48.9%). Approximately a quarter of facilities in Kenya and
Uganda had experienced a TDF stockout in the quarter preceding the survey. In terms of staff-
ing, Ugandan facilities were most likely to have a physician on the ART staff (68.1%) and least
likely to allow nurses to initiate patients (19.1%). More facilities in Uganda (36.2%) than Kenya
(15.7%) reported training staff on HIV in the past year.
The patient sample was 63% female with a median age of 35 years (Table 2). Over a quarter
of patients were missing a baseline CD4 value, and 8% were missing a baseline WHO stage.
Among those with recorded values, the median CD4 count was 173. Patients most commonly
initiated at WHO stage III (37.8%) or II (33.2%), with less than 6% initiating with stage
IV disease.
Fig. 1 illustrates the initial antiretroviral treatment regimens prescribed during our study pe-
riod. Kenya had the highest proportion of patients prescribed d4T-based regimens in 2008
with 73%, followed by Zambia (16%) and Uganda (7%). By 2011, the proportion of patients ini-
tiated on d4T-based regimens had dropped to 12% in Kenya and 1% in Zambia and Uganda.
TDF use rose during the same period, from 3% to 37% in Kenya, 2% to 34% in Uganda, and
64% to 87% in Zambia. Zambian patients were rarely prescribed AZT (6%) in 2011, while it
was common in Uganda (62%) and Kenya (48%).
Table 1. Facility characteristics at time of survey.
Kenya Uganda Zambia Total
N 51 47 48 146
% % % %
Facility owner
Government 90.2 66 68.8 75.3
Private/NGO 9.8 34 31.3 24.7
Complexity
Non-hospital 47.1 38.3 52.1 45.9
Hospital 52.9 61.7 47.9 54.1
Location
Urban 70.6 66 62.5 66.4
Rural 29.4 34 37.5 33.6
ART program age (median (IQR)) 6 (5–8) 7 (5–8) 6 (4–7) 6 (5–7)
Over 5 years 37.3 26.7 38.1 34.1
5 years or less 62.7 73.3 61.9 65.9
ART program has physician 20.8 68.1 42.2 43.6
ARV order quantity is decided internally 98.0 87.2 7.1 66.7
Nurses can initiate patients 34.7 19.1 62.8 38.1
Staff received HIV training in last year 15.7 36.2 . 25.5
Experienced TDF stockout in last quarter 25.5 25.5 . 25.5
Carried TDF in triple dose ﬁxed form 98.0 48.9 . 74.0
doi:10.1371/journal.pone.0120350.t001
Uptake of WHO ART Recommendations
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At the health facility level, we observed variation both within and between countries with re-
gard to the ART regimen at initiation prescribed in a given year. In 2008, the median percent-
age of patients initiated on d4T-based regimens at a given facility was 85% (interquartile range
[IQR]: 76%-94%) in Kenya, 13% (IQR: 5%-22%) in Uganda, and 9% (IQR: 5%-22%) in Zam-
bia. Fig. 2 demonstrates the degree of facility-level variation in the most recent patient cohort
for each country. The median percentage of patients initiated on d4T at a given facility in
2011–2012 in Kenya and Uganda and in 2010–2011 in Zambia was 7% (IQR: 3%-17%), 0%
(IQR:0%-2%), and 4% (IQR: 2%-9%), respectively. Facility-level rates of TDF use in the same
years of initiation were 27% (IQR: 13%-57%) in Kenya, 31% (IQR: 17%-51%) in Uganda, and
83% (IQR: 73%-90%) in Zambia.
The regression analysis using the most recent data from Kenya and Uganda found that initi-
ating in 2012 versus 2011 was significantly associated with a higher probability of receiving
TDF in both countries (Table 3). Patients with a more advanced WHO stage at initiation were
also significantly more likely to begin a TDF-based therapy; compared to patients classified as
WHO stage I, those classified as stage IV had 2.78 (95% confidence interval [CI]: 1.73–4.48)
and 2.15 (95% CI: 1.46–3.17) times the odds of initiating on TDF in Kenya and Uganda, re-
spectively. Having a CD4 test at initiation (regardless of test result) was also a significant pre-
dictor in Uganda (odds ratio [OR]: 1.43; 95% CI: 1.16–1.76). Finally, several facility
characteristics were significantly associated with TDF use in Uganda, including employing a
Table 2. Patient characteristics at initiation.
Kenya Uganda Zambia Total
N 13,135 8,097 8,275 29,507
% % % %
Female 65.9 61.4 58.5 62.6
Age (median (IQR)) 35 (28–43) 35 (29–42) 36 (30–42) 35 (29–42)
18–29 28.9 27.6 23.8 27.1
30–39 37.6 39.3 43.7 39.8
40–49 22.3 22.6 22.7 22.5
50+ 11.3 10.6 9.8 10.7
WHO stage
I 20.4 20.1 24.5 21.5
II 32.5 34.7 23.4 30.6
III 33.6 29 42.3 34.8
IV 3.7 6.3 6.4 5.2
Missing 9.7 9.8 3.5 8
CD4 count (median(IQR)) 173 (79–259) 175 (83–264) 170 (96–256) 173 (86–259)
<50 11.8 13 9 11.4
50–199 27.8 28.6 41.4 31.8
200–349 23.3 25.3 27.3 25
350+ 5.6 6.8 6.4 6.2
Missing 31.5 26.2 16 25.7
Year
2007 14.1 3.9
2008 18.6 11.8 18.9 16.8
2009 20 16.4 27.3 21
2010 25.9 23.1 35.5 27.8
2011 29.4 33.3 4.3 23.4
2012 6.1 15.5 7
doi:10.1371/journal.pone.0120350.t002
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Fig 1. Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by year of treatment initiation.
doi:10.1371/journal.pone.0120350.g001
Fig 2. Percentage of patients on d4T-, TDF-, and AZT-based ART regimens by facility in the most recent years of data available.
doi:10.1371/journal.pone.0120350.g002
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doctor for the ART program (OR: 2.86; 95% CI: 1.48–5.51) and having private or non-govern-
mental organization owner (OR: 2.86; 95% CI: 1.45–5.66).
Discussion
Patient-level data from a wide range of ART facilities in Kenya, Uganda, and Zambia supports
the assertion that national HIV programs have moved quickly to adopt WHO ART first-line
treatment recommendations into clinical practice. By 2011, just one year after formal adoption
of the revised WHO recommendations, all three countries had shifted away from d4T-based
first-line treatment, such that less than 15% of all patients were being prescribed d4T at the
time of treatment initiation.
However, the timing and pace of change varied considerably by country. Both Zambia and
Uganda moved away from initiating patients on d4T prior to the official release of the 2010
WHO guidelines. In Zambia, national guidelines no longer included d4T-based treatment be-
ginning in 2008.[19] Zambia was also one of the earliest sub-Saharan African countries to
adopt TDF, with over a third of initiates receiving TDF as early as 2007. Interestingly, in
Uganda, d4T was still included as a recommended first-line treatment option even as the
phase-out of d4T was occurring through 2008 and 2009.[20] In contrast to Zambia, Uganda
opted for an AZT-based alternative at first, with TDF use only expanding in the more recent
initiates. Kenya, on the other hand, waited to update national policy until it was clear that new
Table 3. Multilevel logistic regression analysis for odds of initiation on TDF-based therapy in 2011–2012.
Kenya Uganda
OR [95% CI] OR [95% CI]
Facility characteristics
Private/NGO owner 0.35 [0.03,3.81] 2.86 [1.45,5.66]**
Hospital 2.83 [0.71,11.22] 0.61 [0.27,1.38]
Rural 0.99 [0.25,3.98] 0.63 [0.32,1.26]
Program is over 5 years old 0.45 [0.15,1.41] 1.93 [0.92,4.02]
ART program has physician 2.29 [0.51,10.35] 2.86 [1.48,5.51]**
Nurses can initiate patients 0.54 [0.19,1.57] 1.42 [0.58,3.44]
Staff received HIV training in last year 1.41 [0.29,6.76] 0.8 [0.42,1.52]
Patient characteristics
Female 1.15 [0.98,1.34] 0.86 [0.73,1.02]
CD4 recorded at initiation 1.16 [0.97,1.39] 1.43 [1.16,1.76]**
Year of initiation (2012 vs 2011) 1.59 [1.30,1.96]** 2.53 [2.07,3.09]**
Age at initiation (reference: under 30)
30–40 1.29 [1.07,1.55]** 1.02 [0.83,1.24]
40–50 1.18 [0.95,1.47] 1.04 [0.83,1.32]
50+ 1.39 [1.07,1.79]* 1.31 [0.98,1.74]
WHO stage at initiation (reference: Stage 1)
2 1.13 [0.92,1.38] 0.88 [0.70,1.10]
3 2.14 [1.74,2.63]** 1.28 [1.00,1.64]
4 2.78 [1.73,4.48]** 2.15 [1.46,3.17]**
Missing 1.09 [0.77,1.54] 1.24 [0.90,1.71]
*p<0.05
**p<0.01
***p<0.001
doi:10.1371/journal.pone.0120350.t003
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WHO guidelines would be released recommending phase-out of d4T.[21] The reason for the
variation in this shift is likely multifold. First, countries with greater confidence in donor fund-
ing may be more willing to adopt more expensive ART medications. Second, countries with a
more established epidemic (e.g., South Africa), and therefore more clinical and donor experi-
ence around HIV treatment, may be more aggressive in making the switch. Finally, it is likely
that while policymakers may respond to early published data (as was the case in Zambia), re-
spected global bodies that synthesize evidence and develop recommendations continue to be
important in influencing policy change as well.
In Kenya and Uganda, drug choices varied substantially by facility. In Uganda, we found
that patients at private facilities were more likely to be prescribed TDF. This finding likely
comes as a result of public facilities following national guidelines that named AZT-based thera-
py as the preferred first-line therapy in 2010, whereas private facilities likely had more leeway
with medication procurement and prescribing patterns.[22] There is also likely to be a signifi-
cant financial component to this, as public facilities are often underfinanced compared to their
private counterparts. The Ugandan government has since revised this to specify TDF-based
therapies as the first choice.[23] Ugandan patients were also more likely to be prescribed TDF
if there was a doctor on staff at the facility and if a CD4 count was performed. These associa-
tions between provider cadre, testing, and drug choice suggest possible relationships between
staff training/expertise and following/understanding guidelines and represent a clear opportu-
nity for further investigation as task shifting has become a key component in enhancing medi-
cal capacity.[24–26]
It is also notable that many facility factors were not significant predictors of regimen type.
Our finding that both hospitals and health centers have similarly moved away from prescribing
d4T is contrary to the results of a smaller study from Lesotho that found decentralized health
centers to be slower in the adoption of alternative regimens.[27] Additionally, rural facilities
performed as well as their urban counterparts when controlling for presence/absence of physi-
cian providers. These are encouraging findings given that ongoing scale-up of national ART
programs will necessitate increased use of lower-level health centers in order to increase overall
ART coverage rates and reach populations with less access to HIV care.
Interestingly, in both Uganda and Kenya, patients classified as WHO stage IV at initiation
had over twice the odds of being prescribed a TDF-based therapy as those classified as stage I.
This could indicate prioritizing TDF for the sickest patients and may be associated with its
higher cost or perceived higher efficacy. Further research examining drug stocks and their rela-
tionship to ART prescribing patterns would better help elucidate this concept.[28]
This study benefits from a large and diverse sample in terms of time, geography, and facility
type, but it is not without limitations. Despite efforts to sample from all patient charts, facilities
use different practices in storing charts of dead or defaulted patients, and this may have differ-
entially affected the sample of charts across facilities. While it is unlikely that charts of patients
initiated on a certain regimen were systematically misplaced or removed, it is possible that pa-
tients initiated on d4T are actually underestimated given that they are at higher risk of default
secondary to medication complications. In addition, we received electronic data records from a
small number of facilities, while for the majority of facilities, chart extractions were done by
hand; therefore, it is possible that the quality of the data and information included differs for
these facilities. However, a separate analyses of these facilities finds that they are within the ex-
pected range of prescribing patterns. Furthermore, since charts were weighted based on the
size of the ART program in the year of ART initiation, we do not expect that the facilities with
electronic records had undue influence on our overall descriptive findings.
In addition to ongoing monitoring of ART prescribing, a key quality metric in evaluating
ART programs, we believe that there should be continued attention to the cost implications of
Uptake of WHO ART Recommendations
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d4T phase-out and TDF scale-up. Since the institution of the 2010 WHO recommendations,
the cost of both AZT and TDF regimens has decreased, although d4T still remains less expen-
sive. Several studies have examined the potential cost effectiveness of switching to a more ex-
pensive TDF-based regimen, taking into account improved adherence, fewer instances of
second-line substitution, and overall improved outcomes.[29][30] While the findings are coun-
try dependent and vary by the national purchase price of TDF, they report that there may actu-
ally be cost savings associated with making such a change. As donor funding for HIV plateaus
or declines and the responsibility for financing ART programs slowly moves from donors to
countries, it will be important to monitor if low-income countries such as Kenya, Uganda, and
Zambia are able to maintain and/or increase ART coverage while utilizing TDF-based treat-
ment regimens.[31–33]
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